MSN Has Green Light To Launch US Entresto Competition, With Trial Around The Corner
US Appeals Court Upholds Denial Of Preliminary Injunction; Key 2026 Patent At-Issue
Will Novartis’ monopoly on Entresto, one of the biggest-selling small molecule drugs in the US, last until its proffered mid-2025 date? An unfavorable decision by the US Court of Appeals for the Federal Circuit that has handed victory to ANDA sponsor MSN Labs could upend the originator’s projection.
